

Do you, or someone you know, have Alzheimer's disease?

**Find out more about how
to get involved in a clinical
research trial called the
MK-7622-012 Trial ...**

About Alzheimer's Disease

Alzheimer's disease is the most common form of 'dementia', a term that covers a wide range of symptoms, including memory loss, mood or personality changes, and problems with communication and judgment. In the US, Alzheimer's affects over 5 million Americans.¹

Alzheimer's disease is a progressive disease, meaning that it worsens over time. In the early stages, only minor changes in a person's mental abilities or behavior may be apparent and daily functioning may only be minimally affected. As the disease progresses, symptoms become more severe, and individuals with Alzheimer's need increasing levels of support to help them manage day-to-day tasks. The people closest to them – family members or other caregivers – play an increasingly important role, providing practical and emotional support, while still enabling their loved ones to retain as much independence as possible for as long as possible.

Although there are certain characteristics that are common in Alzheimer's disease, no two people are likely to experience the disease in the same way, as the symptoms and the rate of decline vary significantly from person to person.

Treatment of Alzheimer's Disease

There is currently no cure for Alzheimer's disease. Treatments are available that may slow the worsening of symptoms or temporarily alleviate the symptoms. However, experts agree that there is a need to undertake further research to find better treatments.

The MK-7622-012 Trial, outlined below, is contributing to this body of research, and is currently looking for individuals with Alzheimer's disease, and their caregivers, to get involved.

¹http://www.alz.org/alzheimers_disease_facts_and_figures.asp#quickFacts

About the MK-7622-012 Trial

The MK-7622-012 Trial is being conducted at approximately 60 centers across the USA and Canada and will enroll up to approximately 830 participants diagnosed with mild to moderate Alzheimer's disease with a history of mental decline over the past year or more.

The trial will assess whether an investigational new drug, when given together with the standard Alzheimer's medication donepezil (Aricept™), has an effect on mental abilities impaired by the disease, such as understanding, reasoning and judgment.

Individuals may qualify for this trial if they:

- **Have a diagnosis of mild to moderate Alzheimer's disease with a history of mental decline over at least 1 year**
- **Are 55 to 85 years of age**
- **Are on a stable dose of donepezil (Aricept™)**

Other requirements will also need to be met to qualify for participation. Potential trial participants will be evaluated by study doctors and nurses to determine eligibility. Investigational study drug, study-related medical care and study procedures will be provided at no charge.

What is Involved for Trial Participants?

All trial participants are required to have a caregiver or trial partner that lives with them or has face to face contact at least 3 days a week for a minimum of 6 waking hours. The caregiver must attend all trial visits, ensure study medications are taken as instructed and provide feedback on how the individual with Alzheimer's disease is responding to study treatment.



Trial duration for each participant will be between 29 to 33 weeks, and each participant and their caregiver will be required to attend up to 10 visits at the study clinic during this time. There will also be telephone contact with the study team.

Participants will be required to take one capsule of the study drug every morning, continue to take any other permitted medications that are permitted while taking part in the trial, and continue with any non-drug treatments, such as day care.

Study staff will monitor the well-being of participants throughout the trial. They will perform physical examinations and collect blood and urine samples for laboratory testing. The study staff will also ask questions about Alzheimer's disease symptoms such as memory, mood and ability to perform daily activities, review medications, and discuss any side effects that may have been experienced.



About Clinical Research Studies

Clinical research studies are designed to answer specific questions about new investigational drugs. An investigational drug goes through several clinical research studies to evaluate its safety and effectiveness. These clinical research studies are performed in accordance with strict governmental guidelines. These guidelines help ensure that the safety and rights of trial participants are protected during the clinical research trial, while allowing valuable information about the investigational drug to be collected. Depending on the results of the studies, an investigational drug may later become available to the wider public.

Because the investigational drug in the MK-7622-012 Trial is still being assessed, there is no guarantee it will improve Alzheimer's disease symptoms of trial participants.

Participating in the MK-7622-012 Trial

If you are interested in participating in the MK-7622-012 Trial, you will go through the informed consent process. This process involves learning the key facts about the clinical research trial to help you decide whether or not you want to join. The study team will explain the details of the trial, including its purpose, duration, what procedures are involved, and possible risks and benefits. You are then invited to sign the informed consent document. This document is not a contract, and you are free to withdraw from the trial at any time and still be eligible to the same standard of care that you received before trial participation. In this trial, the participant and caregiver will be asked to sign separate consent documents.

Contact us to find out more

Participating in a clinical research trial is an important decision. The study team is committed to answering any questions you may have and making sure you understand what is involved.

For more information about this Alzheimer's research trial, please contact us on the number below. We will be pleased to talk to you and you will not be obliged to take part just by asking for further details.

Clinic name: Pacific Neuroscience Medical Group

Contact person: Karen Kearns, Coordinator

Address: 1701 Solar Dr, Ste 140, Oxnard, CA

Telephone: (805) 278-4148